Announcements

Maintaining America's Leadership in Biomedical Innovation: FDA's Role in Advancing U.S. Drug Development Written Testimony
Maintaining America's Leadership in Biomedical Innovation: FDA's Role in Advancing U.S. Drug Development Written Testimony
Read More
Call for Nominations for the 2026 Innovations in Regulatory Science & Policy Awards
The Reagan-Udall Foundation for the FDA invites nominations for its annual Innovations in Regulatory Science & Policy Awards.
Read More
Reagan-Udall Foundation for the FDA Announces New Board Chair; Welcomes New Board Member
(February 6, 2026) The Reagan-Udall Foundation for the FDA (Foundation) has appointed Adrian F. Hernandez, MD, MHS, as Chair of its Board of Directors. Dr. Hernandez, who has served on the Board since 2019, is a cardiologist and the Vice Dean for…
Read More
More Announcements

Coverage

Palvella Therapeutics: Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential to accelerate patient access to effective therapies for significant unmet medical needs.
Read More
Spencer Fane: FDA Leadership Provides Revised Priorities at Reagan-Udall Foundation Annual Board of Directors Meeting
On July 21, the Reagan-Udall Foundation for the Food and Drug Administration held its 2026 Annual Public Meeting of the Board of Directors.
Read More
Legis1: FDA Faces Staffing Crisis Threatening U.S. Drug Innovation
The FDA biomedical innovation hearing featured five witnesses: Susan Winckler from the Reagan-Udall Foundation for the FDA, Aaron J. Kowalski from Breakthrough T1D, Dr. Thomas Hwang from Brigham and Women's Hospital and Harvard Medical School, Dr.…
Read More
More Coverage